asa guidelines for glp-1 drugs How should we approach patients on agonists? Check out this excellent editorial from Dr. Girish Joshi, "Clarifying the and Decoding the Enigma: Strategies Anesthetic Management of Patients on Glucagon-Like Perioperative management of patients taking
Description
Results After 16 weeks, the mean body weight loss was 4.5 kg (95% confidence interval (CI), -6.7 to -2.3 kg

What is NOT a GLP-1 Toujeo is not a GLP-1

This activation slows your stomach's emptying, increases feelings of fullness after smaller meals, and reduces cravings for high-calorie foods

Across trials, 30% to 80% of patients achieve hemoglobin A1c targets below 7%, with semaglutide often producing the greatest reductions

Drug-specific effects are not separated

Blood pressure-lowering effects of incretin-based diabetes therapies
